After this afternoon's 2.1% surge to $139.82 per share, Quest Diagnostics might just keep moving past its target price of $143.86. With an average analyst rating of hold, and target prices from $130.0 to $165.0, the stock's next move is anyone's guess.
Quest Diagnostics's short interest — meaning the percentage of the share float that is being shorted — is lower than average at 2.7%. The stock's short ratio is 2.54. The company's insiders own 0.83% of its outstanding shares, which indicates a strong alignment between management and shareholder interests.
Another number to watch is the company's rate of institutional share ownership, which now stands at 92.2%. In conclusion, we believe there is mixed market sentiment regarding Quest Diagnostics.
Institutions Invested in Quest Diagnostics
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2023-09-30 | Vanguard Group Inc | 12% | 13,624,131 | $1,904,926,096 |
| 2023-09-30 | Blackrock Inc. | 10% | 11,386,506 | $1,592,061,352 |
| 2023-09-30 | State Street Corporation | 5% | 5,341,405 | $746,835,286 |
| 2023-09-30 | Victory Capital Management Inc. | 3% | 3,414,514 | $477,417,372 |
| 2023-09-30 | Wellington Management Group, LLP | 2% | 2,613,793 | $365,460,556 |
| 2023-09-30 | Geode Capital Management, LLC | 2% | 2,473,564 | $345,853,736 |
| 2023-09-30 | Price (T.Rowe) Associates Inc | 2% | 2,207,711 | $308,682,168 |
| 2023-09-30 | JP Morgan Chase & Company | 2% | 2,001,347 | $279,828,352 |
| 2023-09-30 | Dimensional Fund Advisors LP | 2% | 1,972,866 | $275,846,138 |
| 2023-09-30 | Invesco Ltd. | 2% | 1,798,803 | $251,508,648 |
